Bayer's Pivotal Fortnight: Pipeline Progress Meets Legal and Financial Headwinds

Bayer faces a pivotal U.S. Supreme Court hearing on glyphosate litigation while its stroke drug asundexian shows strong trial results. The AGM and financial outlook add to a critical two-week period.

Bayer AG finds itself at a critical juncture, navigating a dense calendar of events that will test both its long-term pharmaceutical pipeline and its immediate financial and legal resilience. Over the next two weeks, the company faces a trifecta of challenges and catalysts: a pivotal U.S. Supreme Court hearing, its annual shareholder meeting, and the publication of promising late-stage clinical data.

The most immediate market focus is on the legal front. On April 27, just three days after Bayer’s virtual Annual General Meeting, the company will appear before the U.S. Supreme Court. The hearing concerning the glyphosate litigation is viewed as potentially decisive for the multi-billion dollar legal overhang that has weighed on the stock for years. The Court’s interpretation of the arguments is expected to shape the investment narrative around Bayer for the foreseeable future, potentially overshadowing other near-term updates.

Amid this legal suspense, the company’s pharmaceutical division has delivered a significant scientific milestone. Data for its investigational drug asundexian, a Factor XIa inhibitor, have been published in the New England Journal of Medicine. The OCEANIC-STROKE trial, involving over 12,000 adults across 37 countries, demonstrated a 26% reduction in recurrent ischemic strokes compared to a placebo. Crucially, the study did not observe an increased risk of bleeding—a common side-effect with anticoagulants—which should facilitate regulatory discussions. The U.S. FDA has already granted the drug Fast-Track designation for stroke prevention.

This success marks a notable turnaround for asundexian, which nearly three years ago saw its OCEANIC-AF study in atrial fibrillation discontinued due to inferiority against an established therapy. The drug is now a central pillar of Bayer’s long-term growth strategy, with management counting on it to drive performance through 2030. It joins other key pharmaceutical assets: Kerendia, which recently gained EU approval for heart failure and is growing at a currency-adjusted 88%, and Nubeqa.

Financially, the picture is mixed. For 2026, Bayer targets group sales between €45 and €47 billion, with adjusted EBITDA expected in a range of €9.6 to €10.1 billion. Core earnings per share are projected between €4.30 and €4.80. However, the free cash flow outlook is less encouraging, forecasted at negative €1.5 to €2.5 billion, which includes roughly €5 billion provisioned for ongoing litigation. Net debt is anticipated to sit between €32 and €33 billion by year-end, underscoring a continued deleveraging challenge.

Reflecting this conservative financial stance, the board has proposed a dividend of €0.11 per share for 2025, to be voted on at the April 24 AGM. The ex-dividend date is April 27, with payment following on April 29.

The stock, trading around €41, sits near its 50-day moving average, indicating a technically neutral position. It remains approximately 16% below its 52-week high from February. The company’s first-quarter results, due on May 12, may struggle for full market attention as investors await the Supreme Court's deliberations. In the agricultural sector, the Crop Science division remains profitable but contends with currency headwinds.

The coming fortnight encapsulates Bayer’s dual reality: promising scientific advancement in its pipeline against a backdrop of persistent legal uncertainty and financial pressure.